EHC

SEC source: 0001127602-24-014370 · form4.xml · nonDerivative · entry 2

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,773

F1 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $83.91 to $84.06, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-014370 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,316

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-014368 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,050

SEC source: 0001127602-24-014083 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,574

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014081 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,589

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014078 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,421

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014076 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,388

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014074 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,220

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014072 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,861

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014070 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,861

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014068 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,782

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-014065 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,050

F1 · shares: Annual grant of restricted stock units pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-013718 · form4.xml · derivative · entry 5

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 25,516 shares

Expires 2026-02-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-24-013718 · form4.xml · derivative · entry 4

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 19,460 shares

Expires 2025-03-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-24-013718 · form4.xml · nonDerivative · entry 3

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 554,098

F1 · price: This per share price is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $83.25 to $83.53, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013718 · form4.xml · nonDerivative · entry 2

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 599,074

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-013718 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 573,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-013024 · form4.xml · nonDerivative · entry 2

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,804

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.65 to $79.67, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013017 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,443

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.45 to $79.67, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013000 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,826

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2023 to defer fixed percentages of their director fees for 2024. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.15 per share paid on April 15, 2024.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $79.43 to $79.62, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-24-013024 · form4.xml · nonDerivative · entry 1

Christie Edward M III · CIK 0001428519 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,490

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013022 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,596

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013019 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,611

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013017 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,032

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013015 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,410

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013013 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,242

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013011 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,883

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment

SEC source: 0001127602-24-013008 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,883

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment

SEC source: 0001127602-24-013005 · form4.xml · nonDerivative · entry 1

CORRELL DONALD L · CIK 0001199794 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,938

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013003 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,072

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-013000 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,592

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On April 15, 2024, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $80.73. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-24-025653 · form4.xml · nonDerivative · entry 2

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,079

F1 · shares: This acquisition is a dividend reinvestment administered by the reporting person's broker. It is eligible for deferred reporting on Form 5 pursuant to Rule 16a-6 but is being reported earlier than required on Form 4.

SEC source: 0001127602-24-007570 · form4.xml · nonDerivative · entry 2

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,652

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007570 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,583

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-007567 · form4.xml · nonDerivative · entry 2

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,077

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007567 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,187

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-007563 · form4.xml · nonDerivative · entry 2

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,773

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007563 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,961

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-007561 · form4.xml · nonDerivative · entry 3

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,227

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007561 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,979

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-007559 · form4.xml · nonDerivative · entry 2

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,594.061

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007559 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,105.061

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-007557 · form4.xml · nonDerivative · entry 2

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 554,098

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-24-007557 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 539,309

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 25, 2022.

SEC source: 0001127602-24-006853 · form4.xml · nonDerivative · entry 3

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 464,598

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-006851 · form4.xml · nonDerivative · entry 3

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,504.061

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-006848 · form4.xml · nonDerivative · entry 4

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 103,159

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-006844 · form4.xml · nonDerivative · entry 3

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,845

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-006841 · form4.xml · nonDerivative · entry 3

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,177

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-24-006836 · form4.xml · nonDerivative · entry 3

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,254

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.